Suppressive long-term antiviral management of hepatitis C virus (HCV) and HIV-1 coinfected subjects (SLAM-C).

Trial Profile

Suppressive long-term antiviral management of hepatitis C virus (HCV) and HIV-1 coinfected subjects (SLAM-C).

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C; Liver disorders
  • Focus Therapeutic Use
  • Acronyms SLAM-C
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Sep 2014 Post-hoc analysis comparing the effect of treatment on bone turnover markers in early versus non-early virologic responders presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 21 May 2012 Actual patient number changed from 330 to 338 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top